Form 4: Strata Medical CEO Granted 63,918 RSUs

Strata Critical Medical, Inc. CEO Louis R. Verdetto received a grant of 63,918 Restricted Stock Units, aligning executive incentives with future company performance.

Summary

• Louis R. Verdetto, CEO of Keystone Perfusion Service and an officer of Strata Critical Medical, Inc. (SRTA), was granted 63,918 Restricted Stock Units (RSUs) on December 2, 2025.
• The RSUs will vest over time, with 25% vesting on September 8, 2026, followed by 6.25% vesting every three months thereafter.
• Any remaining unvested RSUs will vest on September 8, 2029, contingent on Mr. Verdetto's continued service to the Issuer.
• Following this transaction, Mr. Verdetto directly beneficially owns 1,133,793 shares of Class A common stock.
• An additional 132,232 shares of Class A common stock are indirectly beneficially owned through the LOUIS VERDETTO IRREVOCABLE TRUST DATED AUGUST 20 2025, for which Mr. Verdetto serves as trustee.

Sentiment

Score: 7

Explanation: The RSU grant to a key executive is a positive signal of management alignment with shareholder interests and commitment to the company's future, though it is a routine compensation event rather than a major operational announcement.

Positives

• The grant of Restricted Stock Units to a key executive like the CEO aligns management's long-term interests with those of shareholders, incentivizing sustained company performance.
• The vesting schedule encourages the executive's continued service and commitment to the company's strategic objectives over several years.

Future Outlook

The RSU grant and its multi-year vesting schedule indicate an expectation of continued service from Louis R. Verdetto through at least September 2029, aligning his future compensation with the company's long-term performance.

Industry Context

The grant of Restricted Stock Units is a common form of executive compensation in publicly traded companies, designed to attract, retain, and incentivize key management personnel by linking their financial interests to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• RSU grants with multi-year vesting schedules are a standard component of executive compensation packages across various industries, including healthcare and medical services, aiming to foster long-term commitment and performance.
• The structure of vesting, with an initial tranche followed by quarterly vesting, is a typical approach to ensure continuous incentive over the vesting period.

Related Party Transactions

• Louis R. Verdetto indirectly beneficially owns 132,232 shares of Class A common stock through the LOUIS VERDETTO IRREVOCABLE TRUST DATED AUGUST 20 2025, for which he serves as trustee.

Stakeholder Impact

• Shareholders: The RSU grant aligns the CEO's financial incentives with the company's long-term stock performance, potentially benefiting shareholders through enhanced executive motivation.
• Employees: The grant to a senior executive may signal stability and a long-term vision for the company, which can positively influence employee morale and retention.

Next Steps

• The granted Restricted Stock Units will begin vesting on September 8, 2026, with subsequent vesting tranches every three months thereafter, subject to continued service.

Key Dates

Keywords

Strata Critical Medical, SRTA, Louis R. Verdetto, Restricted Stock Units, RSU grant, insider transaction, executive compensation, beneficial ownership, Form 4